1 / 8

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes

Featured Article :. Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. Gayatri Sarkar, May Alattar, Rebecca J. Brown, Michael J. Quon, David M. Harlan, and Kristina I. Rother. Diabetes Care Volume 37: 666-670 March, 2014. STUDY OBJECTIVE.

dunne
Télécharger la présentation

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes Gayatri Sarkar, May Alattar, Rebecca J. Brown, Michael J. Quon, David M. Harlan, and Kristina I. Rother Diabetes Care Volume 37: 666-670 March, 2014

  2. STUDY OBJECTIVE • Exenatide treatment improves glycemia in adults with type 2 diabetes and reduces postprandial hyperglycemia in adolescents with type 1 diabetes • We studied the effects of exenatide on glucose homeostasis in adults with long-standing type 1 diabetes Sarkar G. et al. Diabetes Care 2014;37:666-670

  3. STUDY DESIGN AND METHODS • 14 patients with type 1 diabetes participated in a crossover study of 6 months’ duration on exenatide and 6 months off exenatide • Changes in fasting and postprandial blood glucose and changes in insulin sensitivity before and after each study period were assessed Sarkar G. et al. Diabetes Care 2014;37:666-670

  4. Sarkar G. et al. Diabetes Care 2014;37:666-670

  5. Sarkar G. et al. Diabetes Care 2014;37:666-670

  6. RESULTS • High-dose exenatide therapy reduced postprandial blood glucose but was associated with higher fasting glucose concentrations without net changes in hemoglobin A1c • Exenatide increased insulin sensitivity beyond the effects expected as a result of weight reduction Sarkar G. et al. Diabetes Care 2014;37:666-670

  7. Sarkar G. et al. Diabetes Care 2014;37:666-670

  8. CONCLUSIONS • Exenatide is a promising adjunctive agent to insulin therapy because of its beneficial effects on postprandial blood glucose and insulin sensitivity in type 1 patients Sarkar G. et al. Diabetes Care 2014;37:666-670

More Related